With so much riding on it, the Pan-Mass Challenge raises an extraordinary $64 million for Dana-Farber

There has always been a lot riding on the Pan-Mass Challenge (PMC), the beloved bike-a-thon that is both the nation’s largest single athletic fundraiser and Dana-Farber Cancer Institute’s largest single contributor. During a pandemic that has tested the Dana-Farber and Jimmy Fund community in every way imaginable, the PMC once again rose and rode to the occasion with another tremendous performance when it was needed most.

Powered by committed riders, volunteers, supporters, staff, and corporate sponsors, the PMC raised an incredible $64 million in 2021, its largest gift ever to Dana-Farber. This brings its cumulative fundraising total over the last two years—during the pandemic—to an even more incredible $114 million, and $831 million raised since its inception in 1980. The August 7–8 event drew more than 6,000 riders from 47 states, 2,500 volunteers from 47 states, and 2,500 volunteers from 47 states, including more than 150 Dana-Farber faculty and staff and more than 900 cancer patients and survivors who are considered “Living Proof” of the PMC’s mission.

The 2021 ride marked a return to in-person participation on PMC weekend while still offering a virtual Reimagined option. More than 4,600 riders pedaled 16 routes throughout Massachusetts ranging from 25 to 211 miles, while an additional 1,400 participants reimagined their rides in locations around the world. To maintain safety, the PMC reduced large gatherings, staggered start times, eliminated transportation and lodging, and canceled live social events. According to Billy Starr, founder and executive director of the PMC and an Institute Trustee, such measures required adjustments on everyone’s part, but ultimately enabled the PMC to bring everyone together again and keep the mission on course.

“This mission, community, heart, and empathy have always been core PMC DNA, and I don’t think it’s ever been more demonstrated than this year,” said Starr.

The PMC’s impact is perhaps most powerfully embodied by Living Proof riders like Taylor Chinitz, an eight-year rider who was treated at Dana-Farber for stage III B Hodgkin lymphoma. While she missed the special PMC celebrations she enjoyed in previous years, Chinitz appreciated the more intimate, close-knit camaraderie of riding together with her friends and family as a single unit. Above all, she was glad to be back on the road only a year after her stem cell transplantation, raising funds and awareness for Dana-Farber. Now cancer free, Chinitz said, “I ride so that someday there will be successful treatments for every type of cancer, and more patients bouncing back to live longer, healthier lives.”

PMC riders and their many supporters are motivated by the fact that 100 percent of every rider-raised dollar goes directly to cancer research and care. And with 55% of the Jimmy Fund’s annual revenue stemming from PMC support, this bedrock funding touches every aspect of the Institute’s work. For example, with PMC investment, Dana-Farber was one of the few cancer centers nationwide to keep clinical trials going throughout the pandemic, maintaining a robust slate of more than 1,100 studies that advance potentially lifesaving new therapies for patients who may have otherwise run out of options. PMC support sustains this and other important efforts across Dana-Farber’s labs and clinics, bringing hope to people with cancer across the globe.

Laurie H. Glimcher, MD, Dana-Farber President and CEO, the Richard and Susan Smith Professor of Medicine, and a six-year PMC rider, underscored the PMC’s deep impact and Dana-Farber’s enduring appreciation. “Every dollar raised and mile pedaled brings us closer to changing the future of cancer for patients everywhere,” Glimcher said. “They can rely on Dana-Farber because we can rely on the PMC, and we are very grateful for this incredible community’s commitment.”

Dana-Farber Cancer Institute has been the top-ranked cancer hospital in New England by U.S. News & World Report for 21 consecutive years, and is the only cancer center in the country ranked in the top 4 for both adult and pediatric cancer programs.
Dear Friends,

During the holiday season, I like to reflect on the prior year, acknowledge all there is to be grateful for, and look ahead to the new year with renewed hope. All of us at Dana-Farber have a great deal to be grateful for this year—thanks to you, our remarkable community of donors and friends. The word “philanthropy” means “love of humanity,” and the Dana-Farber and Jimmy Fund community is the embodiment of that philanthropic spirit, making a difference with every gift, large and small that resulted in a remarkable amount of philanthropic support. With your support, the fiscal year that ended on Sept. 30 was the most generous year of giving in our history.

At Dana-Farber, we are moving forward with intention and resolve to accelerate the pace of discovery and provide patient care to more patients and families. From finding new treatments, to providing support for our nurses struggling with burnout, to enabling truly innovative discoveries that change cancer medicine, the effects of every gift go beyond their designation, rippling outward to move us forward.

We have seen this ripple effect in action countless times. A gift you make today to support a particular researcher or program can have an impact on generations of oncologists, and in turn, generations of patients and families who deserve the best, most cutting-edge care that science can offer.

I hope that when you read this issue of Impact, you feel as inspired as I am to be a part of the Dana-Farber community. Let us carry our philanthropic spirit through the holidays and into the new year and continue our important work to defy cancer.

Best wishes for a safe and happy holiday season.

Sincerely,

Melany N. Duval
Senior Vice President and Chief Philanthropy Officer

Thank you to our donors!

Compassionate. Resilient. Determined. Committed. These words describe not only our exceptional researchers and caregivers, and the patients and families whose lives they strive to improve every day, but also our incredible community that strives to support them. Throughout another year of continuing challenges, dedicated Dana-Farber and Jimmy Fund donors and participants came forward with generous gifts and creative efforts to help us prevent, treat, and defy cancer at every turn. Because our collaborative research, clinical trials, and networks of care reach far beyond New England, across the U.S. and around the globe, every gift, large or small, adds up to make a powerful difference for patients everywhere. Thank you for your continuing support!

To learn more, visit DefyCancer.org

THE DANA-FARBER CAMPAIGN: UPDATE

Dana-Farber is pursuing an ambitious, multi-year fundraising effort to change the future of cancer research and care: The Dana-Farber Campaign. This $2 billion campaign is the largest in the Institute’s history and one of the largest ever in the U.S. focused solely on cancer. Our community of support is crucial to this effort. Philanthropy through The Dana-Farber Campaign will accelerate the Institute’s strategic priorities by supporting revolutionary science, extraordinary care, exceptional expertise, and essential opportunities—helping us prevent, treat, and Defy Cancer.

Stories throughout this issue feature recent support for our Exceptional Expertise, such as gifts endowing Dana-Farber Chairs, which recognize exceptional senior faculty and fuel their innovative work; and gifts to support Fellowships, which help aspiring physician-scientists on their path to become the next generation of exceptional leaders. Donors can also endow Investigatorships, which help the Institute attract, retain, and advance the work of exceptional mid-career faculty. During the campaign, generous donors have established 12 new Dana-Farber Chairs, for example, and with your partnership, we can continue this momentum to provide our exceptional experts with the resources they need to change the future of cancer.

The CARES (Coronavirus Aid, Relief, and Economic Security) Act provides expanded tax incentives for 2021. Thank you to our donors!

The CARES (Coronavirus Aid, Relief, and Economic Security) Act provides added tax incentives when you donate gifts of cash. This is great news if you plan to make charitable donations before the end of the year.

IF YOU ITEMIZE YOUR DEDUCTIONS:

Contributions to public charities are generally limited to a percentage of a taxpayer’s adjusted gross income (AGI). The CARES Act lifted the cap on annual cash contributions for those who itemize, increasing it from 60% to 100% of AGI through the end of 2021. Any excess contributions available can be carried over to the next five years.

IF YOU TAKE THE STANDARD DEDUCTION:

The universal charitable deduction has been given a well-deserved upgrade through the end of this year. You can take an additional deduction of up to $300 for single filers and up to $600 for married couples filing jointly.

These tax incentives are available for cash gifts to qualified public charities, like Dana-Farber, and are not available for gifts to donor-advised funds or other supporting organizations.

QUESTIONS?

Contact Erin McKenna at gift.planning@dfci.harvard.edu or 800-535-5577 to learn more about the expanded tax incentives for 2021.

FY21 FUNDRAISING RESULTS

For the fiscal year October 1, 2020 – September 30, 2021

<table>
<thead>
<tr>
<th>Source of Revenue</th>
<th>Total Donors</th>
<th>Total Funds Raised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals</td>
<td>210,251</td>
<td>$402 million</td>
</tr>
<tr>
<td>Corporations</td>
<td>4%</td>
<td>$17,809,808</td>
</tr>
<tr>
<td>Foundations</td>
<td>17%</td>
<td>$68,835,541</td>
</tr>
<tr>
<td>Events</td>
<td>18%</td>
<td>$72,335,259</td>
</tr>
<tr>
<td>Percentage of total funds raised for the Jimmy Fund: $86.9 million</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Portion of total funds raised for the Jimmy Fund: $86.9 million
Donors endow McGraw Chair, a first in head and neck cancers at Dana-Farber

Honoring Robert Haddad, MD, chief of the Division of Head and Neck Oncology, a generous group of like-minded donors came together to establish the McGraw Chair in Head and Neck Oncology at Dana-Farber—the Institute’s first such endowed position in head and neck cancers, which will provide financial resources for the incumbent in perpetuity.

Initiated with a leadership gift of $1.25 million from Elizabeth H. and Robert L.W. McGraw and The Donald McGraw Foundation, Inc., the McGraw Chair represents a key strategic priority of The Dana-Farber Campaign: investing in the exceptional expertise at the heart of the Institute.

“The McGraws have always tried to lead by example,” said Robert “Robin” McGraw, whose family has long supported the Institute and its work in breast cancer research and population science. “Inspired by his incredible care team at Dana-Farber, led by Haddad, McGraw was further motivated ‘to do something—not just show appreciation—but to really help lead the way for research and care in head and neck cancers.’

It became clear to the McGraws that establishing an endowed chair would be one of the most important investments they could make to accelerate scientific discovery in head and neck oncology. Endowed positions for esteemed senior faculty are an important tool for Institute leaders to retain and recruit the best clinicians and scientists from around the world. This vital funding makes it possible for outstanding minds to advance their most innovative research at the earliest stages and bring groundbreaking discoveries to fruition more rapidly. The enduring financial support for endowed chairs provides physician-scientists like Haddad more time to discover and deliver better treatments for patients.

“It is inspiring to see how many came together to stand shoulder to shoulder to make this a reality for Robert,” added McGraw. More than 10 additional donors contributed a collective total of more than $2.5 million to fully endow the position.

As first incumbent of the McGraw Chair, Haddad brings his expertise as an accomplished researcher, physician, lecturer, and mentor. He was instrumental in the phase III studies that led to FDA approval of docetaxel, Nivolumab, and Pembrolizumab for head and neck cancers. Haddad has made many other influential contributions to the field, particularly in the use of checkpoint inhibitors, biologics, and combined modality sequential and concurrent chemoradiotherapy in head and neck cancer.

“I am honored to hold this position and grateful for the added awareness the McGraw Chair brings to head and neck cancers,” said Haddad. “Our donors are amazing ambassadors for Dana-Farber’s mission and their commitment makes a tremendous difference in what we can do ultimately to advance therapies for patients.”

Grateful patient advances research for melanoma

Three years ago, Michael Blitzer was diagnosed with melanoma, and was stunned to learn he may only have five years to live.

“I am a Marine Corps veteran, I thought I was a tough guy,” Blitzer says. “But when someone says you may only have five years left, that makes you pause.”

Since his melanoma diagnosis, Blitzer has been grateful for the thoughtful treatment and seamless collaboration that has driven his care at Dana-Farber, which has extended his prognosis considerably. Inspired, Blitzer recently made a generous $100,000 gift to support the work of his doctor, Elizabeth Bachminder, MD, and her team in Dana-Farber’s Melanoma Treatment Center.

“The cooperation, collaboration, and coordination at Dana-Farber is highly distinctive and differentiating,” Blitzer says. “The comprehensiveness and speed with which everyone works—from the doctors and nurses to the physician assistants and schedulers—is amazing. I’m committed to doing anything that I can to help Dana-Farber maintain such high standards for patient care.

“We are so grateful for Michael’s trust and support,” says Buchminder. “His generosity will expand research into novel immunotherapy treatments and help us better understand the role that the immune system plays in controlling melanoma.”

Thankful for more time, Blitzer spends as much of it as he can sailing on his beloved 72-foot sailboat, which he purchased after receiving his initial diagnosis.

“I’m doing really well,” he says. “I’m still here, and being here is good.”

Kernwood Country Club surpasses $1 million raised for women’s cancers

Kernwood Country Club of Salem, Mass., celebrated 10 years of hosting its Jimmy Fund Golf tournament, Swing to Support Dana-Farber, by surpassing a major milestone: a phenomenal $1 million raised to help Dana-Farber prevent, treat, and defy women’s cancers.

Co-chaired by Robin Dale and Judi Karas, the event began as a women’s only private club fundraiser for Jimmy Fund Golf presented by Mohegan Sun. The entire club gets behind the effort with both members and club staff wearing pink or purple in support of women’s cancers. Participants enjoy a day of golf followed by a night filled with festivities such as a DJ, live and silent auctions, and opportunity drawings, all to advance our lifesaving mission.

10% of all designated gifts supports our Faculty Research Fund to advance Dana-Farber’s research mission
Grateful patients, fellows, colleagues, and friends establish Chair in honor of Robert J. Mayer, MD

For more than 35 years, Robert J. Mayer, MD, served as director of Dana-Farber’s Fellowship Program in Hematology/Oncology, where he mentored hundreds of physicians and researchers who have become world leaders in oncology, won Nobel Prizes, and trained the next generation of leaders right here at Dana-Farber.

It is no wonder, then, that many of Mayer’s former fellows were among the first to contribute to an endowment that would provide lasting funds for the Fellowship Program. In fact, so many colleagues, grateful patients, families, and Friends stepped forward that funding reached a threshold that enabled the establishment of an endowed Dana-Farber Chair for the program. In further recognition of Mayer’s legacy, the Chair will be named for him upon his retirement.

Donors who brought the Chair to fruition include David and Judi Marrus. Judi was treated at Dana-Farber, with Mayer consulting on her case. Grateful for Mayer’s compassion and expertise, David and Judi knew they wanted to support the creation of a Chair in his honor, and made a gift to the effort. “Judi had quite a number of years thanks to Dr. Mayer,” said David Marrus. “We feel an enormous sense of gratitude to Bob—to his humanity, to his constant tending. And we know that what he’s done for us, he’s done for many others.”

The first incumbent of the Chair will be Ann LaCasce, MD, MMSc, current director of the program and another of Mayer’s former fellows.

“The endowed Chair ensures a permanent source of funding for our Fellowship Program, which is the largest hematology/oncology training program in the country and has produced more leaders in oncology than any other program in the nation,” said Laurie H. Glimcher, MD, president and CEO of Dana-Farber and the Richard and Susan Smith Professor of Medicine. “I know this support means the world to Bob, and serves as a meaningful and lasting tribute to how he has shaped the careers of researchers and clinicians over the years.”

“Dr. Mayer is a huge part of what makes Dana-Farber one of the best hospitals in the world,” said Huebner. “He has been a captain of ‘TEAM IRV’ in the Boston Marathon® Jimmy Fund Walk for over three decades. She has been a platelet donor over 250 times, and has been a volunteer Patient Ambassador at multiple Dana-Farber locations. ‘Dana-Farber has been my home away from home; people I’ve met there are lifelong friends,’” Balia says. “I’d love to envision a world without cancer. And I give because I want Dana-Farber to remain one of the top cancer institutions—not just in this country, but the world.’”

Leadership Gifts

The following donors made gifts of $100,000 or more to the Fellowship Program in Hematology/Oncology: Chair at Dana-Farber

Joyce Linde
Richard K. and Nancy K. Lubin
Marrus Family Foundation
Linda D’Orenzo
Peter Palandjian
Leonard M. White

Friends of Dana-Farber get ‘Back in the Swing’ of fundraising

The Friends of Dana-Farber Cancer Institute launched a new event this summer to raise funds for the Institute’s lifesaving mission. Back in the Swing, held at Stone Meadow Golf Center in Lexington, Mass., drew 140 guests to enjoy an afternoon of fresh air and fundraising. The outdoor event provided a socially distanced opportunity for guests to mingle, eat, drink, and practice their golf game, all while raising $178,000 for Dana-Farber.

Guests were treated to an auction and opportunity drawing that included various prizes related to golf, vacation packages around Massachusetts, ticket packages for favorite New England sports, and a scooter donated by Herb Chambers Vespa. During the event, Friends Co-Presidents Gabrielle Baron and Lucy Santos shared inspiring words about Dana-Farber’s mission.

The event was chaired by Jill Papagni, director of business development for BOND Building Construction, Inc., one of the top event sponsors. Other top sponsors included Linbeck, C&W Services, SMC Management Corporation, and VPINE Parking Solutions—all of whom made this beautiful day possible.

Founded in 1976, the Friends of Dana-Farber is a volunteer community of more than 1,200 members who have raised more than $41 million to fund cancer research and patient care programs, including an annual fellowship. The Friends also provide services that enhance Dana-Farber’s healing environment, including gift bags for patients undergoing treatment, a world-class art collection, non-denominational spiritual health programs, and programs to brighten the holidays for patients and families.
Estate gift boosts support for early career physician-scientists and nurses

Remembered by friends and loved ones as an outgoing, lifelong learner, Leonard “Lenny” White left a generous bequest of more than $840,000 to Dana-Farber, in gratitude to the care team that helped him through his treatment for pancreatic cancer.

White’s gift furthers the Institute’s commitment to investing in people—a key pillar of The Dana-Farber Campaign—by supporting early career clinicians through three important efforts: the Newly Licensed Nurse Residency Program under the direction of Anne Gross, PhD, RN, senior vice president for patient care services and chief nursing officer; the Leonard M. White Fund for Young Investigator Research in Pancreatic Cancer under the direction of White’s doctor, Robert Mayer, MD, in consultation with Brian Wolpin, MD, director of the Gastrointestinal Cancer Center and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber; and a very special investment in the Fellowship Program Endowed Chair, newly established in honor of Mayer, who serves as faculty vice president for Academic Affairs and the Stephen B. Kay Family Professor of Medicine (see story on page 4).

“Dr. Mayer is kind, considerate, and a true gentleman,” said Kathy Arnstein, a dear friend of White’s and the executor of his estate. “Lenny always wanted to go to the ‘big’ doctor—the one at the top of their field. He was grateful for the excellent care given to him by Dr. Mayer and the nursing staff.”

White’s gift will have a direct impact on the nursing staff and doctors he so appreciated. The Newly Licensed Nurse Residency Program provides ongoing mentorship and guidance to new nurses, supporting skill development and increasing recruitment and retention.

In the same way, his funding for early career investigators will empower the next generation of oncologists through the creation of a two-year fellowship in pancreatic cancer research. A portion of the estate gift also helped purchase artwork for the newly opened Dana-Farber Cancer Institute – Chestnut Hill location. White loved art and knew the comfort it can bring, and so this serves as a meaningful tribute to the patients seeking treatment.

Taco Bell Foundation supports Dana-Farber’s Student Training Program

W ith the initiative of Regional Taco Bell franchisee Lockwood/McKinnon Company and the support of other New England Taco Bell restaurants, the Taco Bell Foundation recently made a grant of $125,000 to support the Student Training Program (STP) in Dana-Farber’s Office of Workforce Development. The Taco Bell Foundation raises funds with the goal of breaking down barriers to education and career-readiness for young people across the U.S. By providing internships to students in Boston Public Schools, STP aims to help build the next generation of highly skilled, prepared and diverse health care professionals by exposing them to college and career readiness programming early in their education.

Workforce Development engages underrepresented and underserved Boston communities that might not otherwise have the opportunity to participate in such internships. In doing so, STP creates a resource of talent and interest in the health care field that also nurtures Dana-Farber’s ongoing efforts to foster a diverse, equitable, and inclusive environment for both our patients and staff, and to eliminate disparities in cancer care—an important focus of The Dana-Farber Campaign.

“Dana-Farber’s Student Training Program is a perfect match for the mission of the Taco Bell Foundation,” said Roger Lockwood, chairman of Lockwood/McKinnon and a Dana-Farber Trustee. “My family has supported Dana-Farber in a variety of ways for decades, and it’s an honor to use our Taco Bell relationship to create growth opportunities for youth in underserved communities.”

ASH grants propel research by early career scientists

The American Society of Hematology (ASH) has awarded Dana-Farber scientists more than $4 million in grants since 2002. Recently, seven Institute researchers received grants totaling $765,000 from ASH to further their research.

Oreofe Odejide, MD, MPH, received a Clinical Junior Faculty Scholar Award to refine and pilot an intervention for Fear of Cancer Recurrence (FCR), a phenomenon that affects nearly 50% of patients with lymphoma. Han Dong, PhD, received a Basic/Translational Fellow Award to investigate the role of a critical stress pathway in generating natural killer cell memory, which may yield new cancer therapies for patients with poor prognoses.

Roger Belizaire, MD, PhD; Samuel Ng, MD, PhD; and Elisa ten Hacken, PhD, each received Basic/Translational Fellow to Faculty Scholar Awards. Belizaire is investigating oncogenic signaling pathways and novel therapeutic targets in chronic myelomonocytic leukemia. Ng is generating insights into the biology of peripheral T-cell lymphomas that may lead to new therapies for these aggressive types of non-Hodgkin lymphoma. Ten Hacken is investigating the genetic and microenvironmental factors that lead to Richter’s syndrome, a transformation of B-cell chronic lymphocytic leukemia into an aggressive lymphoma.

In addition, two scientists—Francesca Alvarez Calderon, MD, PhD, and Kirsty Hillier, MD—received Research Training Awards for Fellows. Calderon is working toward developing novel immunotherapies for the treatment of B-cell malignancies. Hillier is identifying the mechanisms that lead to a group of related pediatric disorders known as immune cytopenias in which blood cells are destroyed by the immune system.

“ASH is proud to support early career scientists who are pursuing innovative avenues aimed at solving some of the most challenging problems in blood cancers today,” said Martin S. Tallman, MD, ASH 2021 president. “ASH is committed to defeating blood diseases and is proud to partner with talented researchers at institutions such as Dana-Farber in this lifesaving journey.”
Andrew Kaczynski and Rachel Ensign's lives were spented in September 2020 when their baby daughter, Francesca, was diagnosed with atypical teratoid rhabdoid tumor (ATRT), one of the most malignant and aggressive of all brain tumors that affect infants. The family moved from New York to Boston so that Francesca, affectionately called “Beans” by her parents, could receive treatment at Dana-Farber/Boston Children’s Cancer and Blood Disorder Center. Tragically, on Christmas Eve, a few months after her diagnosis, Francesca died. Andrew and Rachel, both journalists, had used social media to share their family’s story during Francesca’s treatment and after her passing. Their candor and vulnerability were matched only by Beans’ joy at life and bravery in the face of her cancer.

“We miss Francesca tremendously every day,” said her mom and dad. “We will always be her parents and our efforts to fight childhood cancer are a way of staying true to our responsibility to take care of her.”

The Team Beans fundraising movement got a boost when Francesca’s story caught the attention of Danielle Pourbaix, a rider in the PMC Winter Cycle, the stationary cycling event at Fenway Park that kicks off fundraising each year for the Pan-Mass Challenge (PMC). Though she had never met the family, Danielle was inspired to reach out to Andrew and Rachel for permission to ride the Winter Cycle in Francesca’s honor. Overwhelmed by the outpouring of support from family, friends, and even strangers, Andrew and Rachel established the Team Beans Infant Brain Tumor Fund at Dana-Farber to maximize the impact of gifts made in Francesca’s memory. With more than $1.5 million raised to date, the Team Beans Fund is supporting Dana-Farber’s new Infant Brain Tumor Program within the Pediatric Brain Tumor Center at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. This specialized, comprehensive research and clinical program spans multiple disciplines—cancer biology, computational biology, neuro-oncology, neuropathology, neurosurgery, and more—and is laser-focused on the treatment and care of the youngest of children.

“Support from Team Beans was instrumental in our ability to launch the new Infant Brain Tumor Program,” said Susan Chi, MD, deputy director of Pediatric Neuro-Oncology. “Treatments are currently limited for ATRT and other malignant and aggressive brain tumors that affect infants—but we hope to change that.”

The Team Beans movement continues to gain momentum. Andrew participated in the PMC as a first-time rider in August 2021 alongside 17 other riders who comprised Team Beans, collectively raising more than $1.1 million through both Pourbaix’s PMC Winter Cycle and Team Beans’ PMC fundraising efforts. The PMC donates 100% of every rider-raised dollar to Dana-Farber and is its largest single contributor, accounting for 55% of the Jimmy Fund’s revenue. Andrew also ran the 2021 Boston Marathon®, raising $200,000 for Team Beans, and has no plans to stop. “Francesca will not get to live the life she should have. She should have been able to build her own story and her own legacy, but Rachel and I will build her legacy for her through the Team Beans Infant Brain Tumor Fund,” said Andrew.

Generous bequest supports patients and families from Maine

It takes some people their entire life to find a place where they feel content, inspired, and completely at home. Mary Stacy was fortunate to find such a place at a young age, and it was where she promised she would spend the rest of her life after she graduated from college: Maine. Mary’s loved ones remember her as a kind woman with a lifelong passion for helping children facing financial or medical challenges—a passion that began during college, when she volunteered at a summer camp for kids with special needs. So, it is fitting that Mary meaningfully included Dana-Farber in her estate plans, making a $270,749 gift to provide financial assistance to patients of all ages from Maine, with a particular focus on pediatric patients.

“We frequently have pediatric patients come to us from Maine for treatments that are not available in their home state—for example, bone marrow and stem cell transplants,” says Joe Chabot, MS, director of the Pediatric Resource Program. “These patients face long hospital admissions and their families often incur significant out-of-pocket expenses related to their care. We are able to alleviate this burden thanks to the generosity of Ms. Stacy.”

Michelle Carrier Murphy, representative for the estate, says, “The fact that Mary’s legacy merges together two of the most important things in her life—the state of Maine and programs benefitting children—comes as no surprise to those who knew her. She would be very pleased to know of the impact she continues to make.”

The Estate of Mary E. Stacy is providing crucial financial assistance to Dana-Farber patients and families from the state of Maine.

Pediatric Cancers

When Dana-Farber was founded in 1947, cancer in children was nearly always fatal. Today, cure rates have improved, and patients in our Jimmy Fund Clinic have access to the most cutting-edge treatments at the #1 pediatric cancer hospital in the U.S. And yet, pediatric cancers are still a leading cause of death among children. Give to The Dana-Farber Campaign and advance our mission to stop every childhood cancer in its tracks.

join us: defycancer.org
If you’ve ever ventured through the doors of a HomeGoods store, you know that every trip is different from the one before. The national home retailer, alongside its sister store Homesense, offers customers an ever-changing selection of merchandise. Last summer, HomeGoods offered shoppers something completely unique: reusable shopping bags featuring the artwork of 12-year-old Mateo, a pediatric patient at Dana-Farber Cancer Institute’s Jimmy Fund Clinic. The limited-edition bags were sold as part of the “HomeGoods Helps Families Fight Cancer” campaign, with proceeds benefitting cancer care and research at Dana-Farber. HomeGoods and Homesense are longtime partners of the Institute, supporting its mission for more than 21 years. In addition to bag sales, customers were invited to make a contribution to Dana-Farber and the Jimmy Fund at checkout. The program raised more than $2.9 million in 2021, a phenomenal contribution to Essential Opportunities in The Dana-Farber Campaign.

This year’s artist, Mateo, was diagnosed with B-cell acute lymphoblastic leukemia (ALL) at just 8 years old. Typically, more than 90% of ALL pediatric patients are cured with chemotherapy, but despite Mateo’s aggressive treatment plan, his chemotherapy was not successful. Oncologists informed the family that Mateo would need a stem cell transplant.

Neither Mateo’s parents nor his three siblings were a close enough match to donate bone marrow. Luckily, several months earlier in Germany, a woman named Laura had stumbled upon a kissk where a nonprofit organization was recruiting bone marrow and stem cell donors. Laura provided a DNA swab in exchange for a chocolate bar. She forgot about the encounter until she received word that she had matched with a patient. She agreed to undergo the procedure to extract her marrow. It was only afterwards that she learned she was Mateo’s only match.

Shortly after his transplant, Mateo developed graft-versus-host disease. It wasn’t long before the cancer was back, and Mateo was told he would need another stem cell transplant. Using Laura’s cells again would be too risky. Fortunately, her bone marrow gave Mateo the extra time needed for scientific discovery to catch up. New drugs made it possible to use donor cells that were not as closely matched to the recipient, and Mateo’s brother Leo was able to donate his stem cells to save his brother’s life.

Today, thanks in part to the cutting-edge research funded by programs like HomeGoods’, Mateo is cancer-free.

“I think this was supposed to happen to me so I could find my true self and inspire other people,” Mateo explains.

Three of Mateo’s drawings were featured on reusable bags at HomeGoods. Each design was shaped by his cancer journey. The elephant is Mateo, strong and sturdy. The bird represents his friend Jordan, a pediatric patient who passed away in 2017. The hearts represent each member of Mateo’s family. And the waterfall is the calm and peaceful energy he wishes for us all.

Patient’s artwork helps HomeGoods raise more than $2.9 million for Dana-Farber

Grateful patient thanks his doctor by funding research

Dana-Farber made me feel like I was getting absolute world-class care, which was necessary,” said Spiegel. An avid free diver and snowboarder, he worried that his diagnosis and treatment would mean lasting damage to his leg. “I remember being almost more scared of that than of anything else. That’s one of the reasons why we wanted the best of the best.”

Luckily, with the help of Wagner and surgical oncologist Chandrjit Raut, MD, MS, Spiegel was soon able to get back on the slopes with his family. And although recently diagnosed with a recurrence of his cancer, he remains hopeful and dedicated to raising awareness and funds for liposarcoma research.

“Whatever I can do to give back to that community of doctors and researchers and nurses, I’d like to try and do,” he said.

“As our team launches new studies into treatments for liposarcomas and reducing the risk of recurrence, we are especially grateful for our generous supporters,” said Wagner. “This kind of funding enables us to accelerate our progress in treating these cancers and ensuring the best possible outcomes for patients during and after treatment.”

The Caroline Fund provides hope for young adults

By the end of her freshman year at Connecticut College, Caroline Grape had already embraced this new stage of her life with force—earning Dean’s High Honors, an invitation to become a Presidential Scholar, and a nomination for Rookie of the Year on the cross-country team. Unfortunately, her epic year drastically changed when a doctor’s examination of a stomach lump ended with a cancer diagnosis. Caroline was diagnosed with translocation-driven sarcoma (CIC-DUX4), an extremely rare and aggressive cancer that affects mostly young adults. Through friends and research, Caroline and her parents found themselves at Dana-Farber under the care of George Demetri, MD, director of the Sarcoma Center, senior vice president for Experimental Therapeutics, and Quick Family Chair in Medical Oncology at Dana-Farber. At the Grape family recalls, “it became apparent to us that Dr. Demetri was renowned globally in the sarcoma community and that the best care and doctors were in our own backyard at Dana-Farber.”

Caroline passed away nine months after her diagnosis, an outcome that is all too common for those with this disease. Her parents established the Caroline Fund in the hope of preventing this from happening to others, like Caroline, on the precipice of their adult life. To date the fund has raised over $500,000 through the generosity of Caroline’s parents, as well as numerous friends and family who all loved Caroline.

“We cannot overstate our appreciation for the Caroline Fund,” said Demetri. “This support will fund robust and much needed research against this rare disease.”

Caroline Grape inspired her parents to support sarcoma research at Dana-Farber.

Dana Farber Cancer Institute
A AACR funds innovative cancer research by early career investigators

The American Association for Cancer Research (AACR) recently awarded seven Dana-Farber scientists grants totaling more than $1.1 million to expedite advances in diverse areas of cancer research.

Sara Buhrlage, PhD, received an AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant to develop chemical compounds that selectively stabilize specific proteins in cancer cells. This work could lead to the design of new medicines that target cancer-fighting proteins known as tumor suppressors, which have tremendous therapeutic potential but cannot be targeted by conventional drugs.

“The caliber of the proposals from Drs. Abravanel and Rosenbluth greatly impressed our Scientific Advisory Board. We are thrilled to support such outstanding scientists and their cutting-edge work in our fight to cure breast cancer,” said John LaMattina, PhD, co-chair of the AACR-MPM Oncology Charitable Foundation’s Scientific Advisory Board.

Kate and Shai Waisman’s generous gift will support the work of Ann Partridge, MD, MPH; founder and director of the Program for Young Women with Breast Cancer at Dana-Farber.

While the reality of a cancer diagnosis is a challenge at any stage of life, there are unique circumstances to being treated for breast cancer at a younger age that can have distinct long-term effects. Ann Partridge, MD, MPH, founder and director of the Program for Young Women with Breast Cancer at Dana-Farber, and her team are dedicated to researching these issues. A generous gift of $280,000 from Kate and Shai Waisman bolsters this important work.

“When I met Dr. Partridge following my own breast cancer diagnosis at the age of 44, her knowledge and compassion put me and my husband at ease,” said Kate Waisman. “She helped me determine how to better address the emotional and psychosocial needs of a young woman facing this disease. These considerations ultimately support clinicians and patients in choosing the right treatment at the right time.

“This gift from Kate and Shai will have a significant impact on the basic and translational research needed in this area, and on our ability to help other patients,” said Partridge, who is also the director of Dana-Farber’s Adult Survivorship Program.

The Terri Brodeur Breast Cancer Foundation (TBBCF) has spent the last 15 years raising funds, spreading awareness, and providing hope for breast cancer patients and survivors. Named in honor of Terri Brodeur, a dear friend of founder Norma Logan, the foundation has contributed to several advances in breast cancer treatment and care over the years.

The foundation recently awarded grants totaling $200,000 to Dana-Farber’s Daniel Abravanel, MD, PhD, and Jennifer Rosenbluth, MD, PhD. Abravanel is studying the biological mechanisms behind estrogen receptor (ER) loss during metastatic breast cancer progression. ER loss limits treatment options and has been found to negatively affect patient outcomes. His research could guide development of novel therapies—or new uses of existing therapies—for metastatic breast cancer, and point to strategies to predict, delay, or even prevent ER loss.

Rosenbluth is investigating early cellular changes associated with breast cancer in order to develop new strategies for prevention. Her team developed a biosbank of tissue samples from patients who are at increased risk for developing breast cancer—for example, those with a BRCA mutation. Rosenbluth aims to use these samples to evaluate whether premalignant cells in breast tissue could be targeted to prevent cancer from developing.

“The caliber of the proposals from Drs. Abravanel and Rosenbluth greatly impressed our Scientific Advisory Board. We are thrilled to support such outstanding scientists and their cutting-edge work in our fight to cure breast cancer,” said John LaMattina, PhD, co-chair of the Scientific Advisory Board at TBBCF.

Over the past 15 years, TBBCF has funded 23 researchers from Dana-Farber for a total of $2.3 million.
Michael C. Gohl Fellowship accelerates lung cancer research

T he Norman J. Fisher and Doris Fisher Foundation pledged $300,000 to establish the Michael C. Gohl Fellowship in Lung Cancer under the direction of Pasi Jänne, MD, PhD, director of Dana-Farber’s Carole M. and Philip L. Lowe Center for Thoracic Oncology; Robert and Renée Beller Center for Applied Cancer Science, and Chen-Huang Center for EGFR Mutant Lung Cancers. This fellowship will advance the careers of a young investigator while supporting lung cancer efforts in the Lowe Center. Claudia Gohl became acquainted with Dana-Farber in 2013 when her late husband, Michael, was diagnosed with lung cancer despite being a nonsmoker. After his passing in 2016, Claudia, her sister Nina Fisher, and brother-in-law Tom DeKornfeld made a gift through the foundation to establish the Gohl Family Lung Cancer Research Fund at Dana-Farber. 

With this new funding, Jänne and his colleagues are pursuing a multi-pronged approach for treating lung cancers including targeted therapies, immunotherapy, and combination treatments. He hopes to accelerate cutting-edge studies and deliver durable and effective therapies to lung cancer patients. “My team and I are always striving to find the most effective way to combat generic mutations in lung cancer,” said Jänne. “The Michael C. Gohl Fellowship will help to train the next generation of cancer scientists by bringing in a top young investigator and simultaneously propel our research forward.”

“Dana-Farber is one of the best hospitals for cancer care, and I am very impressed with their work,” said Gohl. “We couldn’t think of a better place to make a gift, especially during their campaign.”

Family history of giving inspires gift to lung cancer research

F or the Cyker Family, charitable giving is inherent to who they are. Michael Cyker was a Holocaust survivor, and his son Howard remembers his father’s gratitude for life and a fresh start in America. Michael passed away in 1993 from colon cancer, but not before instilling in his children the importance of giving back. “Dana-Farber has always been a top cause that we give to because of our father,” said Howard. “And from my personal experience, it’s one of the best places in the world for cancer care.”

Howard underwent treatment for lung cancer in 2020, overseen by Bruce Johnson, MD, and David Konnmo, MD, PhD. And just like their father years before, Howard and his brothers were inspired to give in support of research at the Institute. With the Cykers’ generous $100,000 gift, Johnson will further his research into customizing treatments and mitigating side effects for lung cancer—an especially important focus for Howard. He would like to see more definitive data to support treatment options available for future patients.

Howard Cyker celebrating the end of his first PMC ride in August 2021.

As an avid cyclist, Howard’s surgery and cancer treatments left him at approximately 65% lung capacity, which made the prospect of cycling quite a challenge. Despite this setback, he remains grateful and motivated. He was even able to get back into cycling in 2021, and rode in his very first Pan-Mass Challenge (PMC). Even more gratifying, both of Howard’s sons donated to support his PMC ride—extending their grandparent’s generous legacy to a new generation.

Caroline’s Crusaders lace up for IBC research

T here were few silver linings of the COVID-19 pandemic, but for Caroline McGuirk, temporarily relocating back to Massachusetts to be closer to family was one of them. It put her in Dana-Farber’s backyard when she was diagnosed with inflammatory breast cancer (IBC) in December 2020.

Caroline’s family and friends were determined to find a way to support her despite being unable to accompany her to treatment due to visitor restrictions. In honor of Caroline’s birthday in April, her sister Katie launched a fundraiser in support of IBC research guided by Caroline’s oncologist, Filipa Lynce, MD, director of the Inflammatory Breast Cancer Program at Dana-Farber’s Susan F. Smith Center for Women’s Cancers. The fundraiser culminated with a Virtual 5K Run/Walk to Conquer IBC in July 2021, when over 100 participants from all over the world ran, walked and walked in custom race bibs. Locally, Caroline, Katie, and a small group of family members and friends gathered on July 4th in their hometown of Danbury, Mass., to walk the 5K together. Nearly 1,000 donors have contributed to the $100,000 fundraising commitment. “I have been blown away by the strength and positivity Caroline has shown throughout treatment. The funds raised are a testament to the incredible person that she is,” says Katie. “Dana-Farber is one of few institutions in the world with a dedicated IBC program,” adds Caroline. “We’ve found a lot of hope in being somewhere with such expertise as we navigate the path forward, and we’re optimistic that funding further research will meaningfully change the course of this disease and give future patients that same hope.”

Free ME from Lung Cancer Fund fuels immunotherapy research

When Debra Violette was diagnosed with lung cancer, she quickly realized that more needed to be done to prevent and treat the disease. In 2012, after years of experience and advocacy, Debra founded Free ME from Lung Cancer (FMFLC), a Maine-based nonprofit dedicated to raising money for lung cancer research, education, and advocacy.

Living up to its mission, FMFLC made a gift of $100,000 to support research in the Carole M. and Philip L. Lowe Center for Thoracic Oncology at Dana-Farber, carried out by Julia Rotow, MD, and overseen by Pasi Jänne, MD, PhD; director of the Lowe Center, the Robert and Renée Beller Center for Applied Cancer Science, and the Chen-Huang Center for EGFR Mutant Lung Cancers; and Bruce Johnson, MD.

The CDC states that more people in the United States die from lung cancer than any other cancer, creating an urgency for more effective treatments and earlier detection. The development of checkpoint inhibitor immunotherapies transformed the treatment of non-small cell lung cancer (NSCLC) and offers potential for long-lasting responses to therapy. However, patients with oncogene-driven NSCLC rarely respond to the same immunotherapy, posing challenges for longer-term outcomes. With funding from FMFLC, Rotow will characterize how to integrate immunotherapy into the treatment of patients with oncogene-driven NSCLC.

“At FMFLC, we’re committed to making lung cancer a national priority,” said Debra Violette, president and CEO. Free ME from Lung Cancer. “We’re proud to support groundbreaking research at Dana-Farber to advance early detection and prevention of lung cancer.”

Supporters from across the country and around the world took part in the virtual 5K to support treatment options available for future patients.
Dana-Farber Falmouth Road Race team returns to the course in a big way

The Dana-Farber team celebrated its 18th year in the ASICS Falmouth Road Race by raising more than $525,800 for the Jimmy Fund.

On Sunday, Aug. 15, Dana-Farber runners joined a field of 9,500 total participants in the historic summer race. The event returned to its scenic 7-mile route from Woods Hole to Falmouth Heights after an entirely virtual run in 2020 due to the COVID-19 pandemic. In 2021 participants were permitted to run in-person or virtually at a location of their choosing, with 85% of Dana-Farber’s 188-person team choosing to run in person.

Lacing up for the event was an exciting moment for all, especially those close to Dana-Farber’s mission, for whom the race represented much more than a 7-mile journey.

When Elizabeth Grip was diagnosed with essential thrombocythemia (ET), a chronic blood cancer, in 2016, she struggled to comprehend the reality that she would be managing the illness for the rest of her life. While initially easy to control, Elizabeth’s ET necessitated more advanced care starting in 2020, which is when she began treatment with Dana-Farber’s Ann Mullally, MD.

Grip formed Team Laps for Lab Mullally, a fundraising group on Dana-Farber’s Falmouth team, to raise funds for Mullally’s lab. Grip’s team surpassed their fundraising goal and raised more than $25,000.

“I’m running to not only raise awareness for ET, but also to help control what I can—and that’s raising money for Dr. Mullally’s lab in the hopes of a better long-term treatment for ET in the future,” said Grip.

SURGE toward health equity

Cancer clinical trials provide access to novel therapeutics to improve outcomes and survival for patients diagnosed with cancer. Despite being disproportionally affected by gastrointestinal and other cancers, many who are racial, ethnic, language, or age minorities remain disproportionately under-enrolled in these novel therapeutic studies. When groups of people are regularly left out of cancer research and science, the true breadth of patient responses to treatments and their side effects is not recorded, and this incomplete data shapes treatment practices.

More immediately, underrepresented patients may not have access to the latest therapies that could make a critical difference to their health.

As part of its landmark 2020 commitment to give $50 million over 5 years to health equity programs, Bristol Myers Squibb made a charitable grant of $250,000 to support Dana-Farber’s project SURGE: Supporting UnderRepresented minority patients in Genomics-based cancer trial Enrollment. "Bristol Myers Squibb is pleased to support Dana-Farber’s innovative efforts to drive truly inclusive research and greater diversity in clinical trials,” said Alison Handler, PharmD, RPh, director, Health Equity & New Partnerships, BMS Patient Advocacy, Corporate Affairs.

Led by Nadine McCleary, MD, MPH, the SURGE project develops and tests methods to ensure patients from historically under-enrolled groups have the information, personalized support, and genomic matching services needed to opt-in to the latest clinical trials. Efforts like these to reduce cancer disparities are a strategic priority of the Dana-Farber Campaign.

"Underrepresentation in clinical trials is a persistent, systemic problem,” says McCleary. “We need rigorous, systemic solutions to help patients and strengthen cancer medicine."

In 2020, gastric and esophageal cancers collectively caused the death of 1.3 million people worldwide, according to the World Health Organization’s International Agency for Research. The second leading cause of cancer-related mortality, these diseases carry poor prognoses because they are largely unresponsive to chemotherapy. To meet the urgent need for new treatments, the DeGregorio Family Foundation awarded a $200,000 grant to Dana-Farber’s Nilay Sethi, MD, PhD, who is pursuing a therapeutic approach that has shown promise against certain subtypes of gastric and esophageal cancer.

His preclinical research suggested that these malignancies may be halted by drugs that block cellular response to DNA damage, called DNA damage response inhibitors. To investigate this hypothesis, Sethi will leverage the foundation’s funds to test DNA damage response inhibition in the lab.

“Our lab is grateful for receiving grant support from the DeGregorio Family Foundation,” said Sethi. “The funding will directly guide research efforts towards understanding the potential for a new class of therapeutics yet to enter the gastric and esophageal cancer treatment space.”

“We are proud to support Dr. Nilay Sethi and the important work he is doing at Dana-Farber to lay the foundation for the next generation of gastric and esophageal cancer therapeutics,” said Lynn DeGregorio, president and founder of the DeGregorio Family Foundation. “We also commend Dana-Farber’s ongoing commitment to research that is transformative in the field.”

Grant advances research in gastric and esophageal cancers

In 2020, gastric and esophageal cancers collectively caused the death of 1.3 million people worldwide, according to the World Health Organization’s International Agency for Research. The second leading cause of cancer-related mortality, these diseases carry poor prognoses because they are largely unresponsive to chemotherapy. To meet the urgent need for new treatments, the DeGregorio Family Foundation awarded a $200,000 grant to Dana-Farber’s Nilay Sethi, MD, PhD, who is pursuing a therapeutic approach that has shown promise against certain subtypes of gastric and esophageal cancer.

His preclinical research suggested that these malignancies may be halted by drugs that block cellular response to DNA damage, called DNA damage response inhibitors. To investigate this hypothesis, Sethi will leverage the foundation’s funds to test DNA damage response inhibition in the lab.

“Our lab is grateful for receiving grant support from the DeGregorio Family Foundation,” said Sethi. “The funding will directly guide research efforts towards understanding the potential for a new class of therapeutics yet to enter the gastric and esophageal cancer treatment space.”

“We are proud to support Dr. Nilay Sethi and the important work he is doing at Dana-Farber to lay the foundation for the next generation of gastric and esophageal cancer therapeutics,” said Lynn DeGregorio, president and founder of the DeGregorio Family Foundation. “We also commend Dana-Farber’s ongoing commitment to research that is transformative in the field.”

It’s an ideal time to donate appreciated securities

Gifts of stock, mutual funds, bonds, or other publicly traded securities can provide you with potential tax savings while supporting our mission to defy cancer.
Dana-Farber’s global leadership in cancer medicine is propelled by philanthropic funding of its world-class research enterprise.

To that end, 10 percent of all restricted gifts is directed to the Faculty Research Fund (FRF), allowing the Institute to make strategic investments in exceptional faculty, state-of-the-art infrastructure, and bold discovery science throughout Dana-Farber. Since 2013, the FRF has generated more than $45.5 million to elevate the Institute’s scientific excellence, particularly in those fields that span all types of cancer and offer vast potential to drive progress for patients today and generations to come.

During fiscal year 2021, $8.3 million from the FRF was allocated to support selected, Institute-wide objectives. This included funding directed to faculty recruitment and retention, as well as the Trustee Science Committee (TSC) Fellowship, a two-year opportunity for postdoctoral investigators who are pursuing the most promising, high-risk, high-reward projects. As the first Institute-sponsored fellowship open to early-career scientists, the TSC Fellowship trains the next generation of leaders in cancer medicine while accelerating groundbreaking studies that might not otherwise move forward. Additionally, FRF allocations in fiscal year 2021 advanced Dana-Farber’s efforts in strategic centers. This includes cutting-edge, collaborative efforts in genomics, precision immunoncology, prevention and early detection, drug development, epigenetics, and data science.

The FRF is a tremendous example of what is possible when pooled philanthropic resources are strategically and efficiently deployed to meet the goal we all share: defying cancer. Driven by this purpose, the FRF’s impact continues to be seen and felt throughout Dana-Farber in transforming the trajectory of cancer and improving the lives of patients everywhere.

### FY21 Faculty Research Fund

During Fiscal Year 2021, $8.3 million in Faculty Research Fund dollars were directed toward initiatives including faculty recruitment and retention, the Trustee Science Committee Fellowship, and strategic center support.

### Impact

**LATE FALL 2021 | Volume 24 Issue 5**

**National Brain Tumor Society supports vital research for aggressive brain tumors**

**Keith Ligon, MD, PhD, received a $500,000 grant from the Accelerate Brain Cancer Innovation Fund, an affiliate of the National Brain Tumor Society (NBTS), to support correlative research for the Allele GBM Biomarker Consortium and the INSIGHT trials. Ligon’s research focuses on glioblastoma (GBM), which accounts for almost half of all primary malignant brain tumors. In 2016, Dana-Farber and its partner hospitals, with partnership and support from Accelerate Brain Cancer Cure, launched the Allele GBM Biomarker Consortium to help expand and better integratecorrelative research into GBM clinical trials. As part of this effort, patients with newly diagnosed GBM are invited to donate tumor samples for genomic sequencing. The resulting reports, which are generated at no cost to the patient, can be used to rapidly determine next steps in diagnosis and care, as well as if the patient is eligible to enroll in an existing clinical trial. Similarly, INSIGHT aims to leverage biomarker information to improve trial outcomes and speed drug development. With a standard radiochemotherapy arm as a baseline, researchers use biomarker data generated by the Allele Consortium, in addition to other genetic information, to randomize patients to participate in phase 2 trials involving targeted therapies and immunotherapies that are most likely to be of benefit. This statistical approach allows scientists to more rapidly determine the efficacy of specific drugs, expediting the path to phase 3 trials—and these “smart trials” are at the leading edge of trial development.

In support of these two intertwined research efforts, Ligon and colleagues are leveraging his grant to continue to sequence tumor samples from patients who stop responding to therapy to better understand mechanisms of resistance, as well as conduct additional drug studies in research models—generating important data that will hopefully lead to better outcomes for patients. Additionally, data from this study will be made available to other researchers through the National Cancer Institute.

The grant to Ligon reflects the shared recognition of the funders and investigators that each patient is unique, and that patients with brain tumors urgently need therapies that are well matched to their cancer. David Aron, chief executive officer of National Brain Tumor Society added, “We are pleased and honored to help realize the vision of Dr. Ligon, his colleagues, and our partner organizations, to systematically seek out personalized and transformative new treatments for brain tumor patients.”

**Sources of Revenue**

- **70%** Faculty Support
  - $5.9M

- **30%** Strategic Centers
  - $2.5M

---

**National Brain Tumor Society**

[Image of the National Brain Tumor Society logo]

**National Brain Tumor Society supports vital research for aggressive brain tumors**

**National Brain Tumor Society**

[Image of the National Brain Tumor Society logo]

**National Brain Tumor Society**

[Image of the National Brain Tumor Society logo]
The Jimmy Fund’s historic partnership with the Boston Red Sox continued its proud tradition on August 19 as the team’s Triple-A minor league affiliate, the WooSox—Worcester Red Sox—hosted Jimmy Fund Night at Polar Park. Dana-Farber patients were honored at the event, and nurses from Dana-Farber Brigham Cancer Center at Milford Regional Medical Center (above) threw out the first pitch, cheered on by Larry Lucchino, Chairman of the Jimmy Fund, Dana-Farber Trustee, Chairman/Principal Owner of the Worcester Red Sox, and President/CEO Emeritus of the Boston Red Sox.

CALANDER OF EVENTS

For more information on all Jimmy Fund and Dana-Farber events and programs, go to JimmyFund.org or Dana-Farber.org

**NOVEMBER 30**

**Giving Tuesday**

With your help, we have the power to defy cancer. On this global day of generosity, your gift will be doubled, thanks to a $50,000 matching challenge from Arbella Insurance. Visit JimmyFund.org/GivingTuesday or contact Ashley Armstrong at Annual_Giving@dfci.harvard.edu.

**NOW–DECEMBER**

**Holiday Patient Assistance**

Help brighten the holidays for patients in financial need. Your contribution helps to put a holiday meal on the table or purchase gifts for loved ones. Visit JimmyFund.org/HolidayGiving or contact Hannah McCoy at Holiday_Assistance@dfci.harvard.edu.

**DECEMBER 31**

**Dana-Farber Holiday Cards**

Embrace a holiday tradition that’s full of hope. Purchase cards to spread cheer while making a difference in the fight against cancer. View the complete collection and order online at DanaFarberHoliday.org.

**MARCH 1**

**Palm Beach Breakfast with the Doctors**

Discuss the latest breakthroughs in revolutionary science and extraordinary care with Dana-Farber’s exceptional physician-scientists at this compelling annual event, hosted by the Schlager/Weinstein Family. Contact Debra Van De Water 901-833-2080 or Debba_Van_De_Water@dfci.harvard.edu.

**MARCH 2**

**Palm Beach Campaign Leadership Recognition Dinner**

This elegant gathering at The Breakers celebrates the support of our generous Palm Beach community for the Dana-Farber Campaign. By invitation only, Contact Karen Martinez 561-833-2080 or Karen_Martinez@dfci.harvard.edu.

**YEAR ROUND**

**Behind the Breakthroughs**

This webinar series offers an inside look at the latest innovations in revolutionary science and extraordinary care at Dana-Farber. From the comfort of your own home, join the discussion with our exceptional experts to learn how Dana-Farber’s advancements in cancer research and care are possible because of your support. Visit Dana-Farber.org/How-You-Can-Help/Get-Involved/Behind-the-Breakthroughs or contact Kate Rosati at DFCIandJimmyFundEvents@dfci.harvard.edu.

**YEAR ROUND**

**Jimmy Fund Golf**

Presented by Mohegan Sun

Get on the right course to fight cancer® with Jimmy Fund Golf presented by Mohegan Sun. Plan your own golf tournament or mini golf event, or play in an existing event! Visit JimmyFundGolf.org or contact Mary Kate Morrissey at JimmyFund_Golf@dfci.harvard.edu.

**YEAR ROUND**

**Jimmy Fund Let’s Game®**

Attention content creators and gamers! No matter your location, no matter your game, you can make a difference in the lives of cancer patients. Host your own livestream on your favorite platform using Jimmy Fund fundraising and donation tools. Visit JimmyFundLetsGame.org or contact Kenneth Chamberlain at JimmyFund LetsGameinfo@dfci.harvard.edu.